[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.249.135. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1982

Experimental Stromal Herpes Simplex KeratitisInfluence of Treatment With Topical Bromovinyldeoxyuridine and Trifluridine

Author Affiliations

From the Eye Research Laboratory, Ophthalmological Clinic (Drs Maudgal and Missotten); the Rega Institute for Medical Research (Dr De Clercq and Mr Descamps); and Department of Biotechnical Sciences (Dr Wijnhoven), Katholieke Universiteit Leuven, Leuven, Belgium.

Arch Ophthalmol. 1982;100(4):653-656. doi:10.1001/archopht.1982.01030030655027
Abstract

• Two compounds, bromovinyldeoxyuridine ([E]-5-[2-bromovinyl]-2′-deoxyuridine) and trifluridine (5-trifluoromethyl2′deoxyuridine) were compared for their efficacy in the topical treatment of experimental stromal herpetic keratitis produced by the injection of live herpes simplex virus, type 1, into the corneal stroma of rabbits. The trifluridine was used as 1% eyedrops, whereas bromovinyldeoxyuridine was used as either 0.1% or 0.5% eyedrops. All three treatment regimens caused a substantial healing of stromal disease in comparison with placebo treatment. The bromovinyldeoxyuridine (whether used as 0.1% or 0.5%) proved superior to 1% trifluridine eyedrops when the treatment was started one day after virus inoculation. However, bromovinyldeoxyuridine and trifluridine were equally effective if the treatment was started seven days after infection. The 0.5% bromovinyldeoxyuridine eye-drops seemed to be more effective in controlling the complicating severe iritis and secondary glaucoma than either 0.1% bromovinyldeoxyuridine or 1% trifluridine. No toxic effects were observed with bromovinyldeoxyuridine in any eye, whereas 1% trifluridine produced punctate epitheliopathy in some eyes.

×